

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

PALIPERIDONE EXTENDED-RELEASE TABLETS OBTAINS DRUG REGISTRATION APPROVAL

The board of directors (the “**Board**”) of the CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Paliperidone Extended-Release Tablets (3mg, 6mg) (the “**Product**”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.* (石藥集團歐意藥業有限公司), a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.

Paliperidone is a second-generation antipsychotic, with its mechanism of action thought to be mediated by the combined antagonism of central dopamine 2 receptor and 5-hydroxytryptamine 2 receptor. Clinical studies have demonstrated that paliperidone has a rapid onset of action, which can effectively control various types of psychotic symptoms, significantly improve patient functioning, and reduce the relapse rate with a good safety profile, making it a first-line drug for the treatment of schizophrenia. The Product is indicated for the treatment of schizophrenia in adults and adolescents aged 12 to 17 years who weigh at least 29kg. It features a complex design of three-layer osmotic pumps that enables continuous and stable release of the drug, ensuring stable plasma concentration and reducing adverse reactions.

The approval of the Product will further enrich the Group’s product portfolio for neurological and psychiatric diseases.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 14 June 2023

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.

** For identification purposes only*